Medical Advocates

Fosamprenavir (Lexiva/GW433908)
 


 
Conference Citations
 
XIX International AIDS Conference
6th IAS Conference


 
 

Fosamprenavir Main Page Main New/Newsworthy  Home Page      

Last Update:  July 30, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
XIX International AIDS Conference
 


6th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

  • POSTER
    Use and safety of fosamprenavir in HIV-infected children in the European Union: an ongoing
    post-marketing surveillance study
    A. Judd, L. E, L. Galli, T. Goetghebuer .et al
    Poster     Abstract
  • POSTER
    A pilot study of the impact of switch to fosamprenavir and addition of lovaza for treatment of hypertriglyceridemia in
    HIV-infected subjects on antiretroviral therapy (ARVs)
    F. Felizarta, A. Scarsella, H. Khanlou, et al
    Poster     Abstract
  • POSTER
    Hepatic safety profile of fosamprenavir (FPV)-containing regimens in HIV-1-infected subjects with or without hepatitis C
    (HCV) or B (HBV) co-infection
    B. Ha, B. Wine, M. Wisniewski,et al
    Poster     Abstract
  • Pharmacokinetics, cord blood concentrations, and tolerability of boosted fosamprenavir (FPV) in pregnancy
    M. Cespedes, S. Ford, G. Pakes, et al
    Abstract


Fosamprenavir Main Page Main New/Newsworthy  Home Page      

Fosamprenavir Conference Citations